Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors
Structural coverage of the human kinome has been steadily increasing over time. The structures provide valuable insights into the molecular basis of kinase function and also provide a foundation for understanding the mechanisms of kinase inhibitors. There are a large number of kinase structures in t...
Gespeichert in:
Veröffentlicht in: | Journal of medicinal chemistry 2015-01, Vol.58 (1), p.466-479 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 479 |
---|---|
container_issue | 1 |
container_start_page | 466 |
container_title | Journal of medicinal chemistry |
container_volume | 58 |
creator | Vijayan, R. S. K. He, Peng Modi, Vivek Duong-Ly, Krisna C. Ma, Haiching Peterson, Jeffrey R. Dunbrack, Roland L. Levy, Ronald M. |
description | Structural coverage of the human kinome has been steadily increasing over time. The structures provide valuable insights into the molecular basis of kinase function and also provide a foundation for understanding the mechanisms of kinase inhibitors. There are a large number of kinase structures in the PDB for which the Asp and Phe of the DFG motif on the activation loop swap positions, resulting in the formation of a new allosteric pocket. We refer to these structures as “classical DFG-out” conformations in order to distinguish them from conformations that have also been referred to as DFG-out in the literature but that do not have a fully formed allosteric pocket. We have completed a structural analysis of almost 200 small molecule inhibitors bound to classical DFG-out conformations; we find that they are recognized by both type I and type II inhibitors. In contrast, we find that nonclassical DFG-out conformations strongly select against type II inhibitors because these structures have not formed a large enough allosteric pocket to accommodate this type of binding mode. In the course of this study we discovered that the number of structurally validated type II inhibitors that can be found in the PDB and that are also represented in publicly available biochemical profiling studies of kinase inhibitors is very small. We have obtained new profiling results for several additional structurally validated type II inhibitors identified through our conformational analysis. Although the available profiling data for type II inhibitors is still much smaller than for type I inhibitors, a comparison of the two data sets supports the conclusion that type II inhibitors are more selective than type I. We comment on the possible contribution of the DFG-in to DFG-out conformational reorganization to the selectivity. |
doi_str_mv | 10.1021/jm501603h |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4326797</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1645773627</sourcerecordid><originalsourceid>FETCH-LOGICAL-a471t-4e6b0107f7bf88651ea3ad573875ef57d96145419ef9b4157376c869d699672e3</originalsourceid><addsrcrecordid>eNptkV9rFDEUxYModlt98AtIXgT7MG3-Z-ZFqKttl1YqWH0NmZmkk2Um2SYZYf30Ztm6KPhy78P9nXMPHADeYHSGEcHn64kjLBAdnoEF5gRVrEbsOVggREhFBKFH4DilNUKIYkJfgiPCmaxrIRbg1zJ4G-Kkswtej_CijG1yCQYL82Dgp8ur6m7O8MZ5nQz8ErKzUPsefnShG8zkuiL6GoN1o_MPO9W3HOcuz1GP4xb-0KPrdTY9vN9uDFyt4MoPrnU5xPQKvLB6TOb10z4B3y8_3y-vq9u7q9Xy4rbSTOJcMSNahJG0srUlM8dGU91zSWvJjeWybwRmnOHG2KZluByk6GrR9KJphCSGnoAPe9_N3E6m74zPJZzaRDfpuFVBO_XvxbtBPYSfilEiZCOLwfsngxgeZ5OymlzqzDhqb8KcFBaMS0kF2aGne7SLIaVo7OENRmrXlTp0Vdi3f-c6kH_KKcC7PaC7pNZhjqWb9B-j3xOBnAE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1645773627</pqid></control><display><type>article</type><title>Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors</title><source>MEDLINE</source><source>ACS Publications</source><creator>Vijayan, R. S. K. ; He, Peng ; Modi, Vivek ; Duong-Ly, Krisna C. ; Ma, Haiching ; Peterson, Jeffrey R. ; Dunbrack, Roland L. ; Levy, Ronald M.</creator><creatorcontrib>Vijayan, R. S. K. ; He, Peng ; Modi, Vivek ; Duong-Ly, Krisna C. ; Ma, Haiching ; Peterson, Jeffrey R. ; Dunbrack, Roland L. ; Levy, Ronald M.</creatorcontrib><description>Structural coverage of the human kinome has been steadily increasing over time. The structures provide valuable insights into the molecular basis of kinase function and also provide a foundation for understanding the mechanisms of kinase inhibitors. There are a large number of kinase structures in the PDB for which the Asp and Phe of the DFG motif on the activation loop swap positions, resulting in the formation of a new allosteric pocket. We refer to these structures as “classical DFG-out” conformations in order to distinguish them from conformations that have also been referred to as DFG-out in the literature but that do not have a fully formed allosteric pocket. We have completed a structural analysis of almost 200 small molecule inhibitors bound to classical DFG-out conformations; we find that they are recognized by both type I and type II inhibitors. In contrast, we find that nonclassical DFG-out conformations strongly select against type II inhibitors because these structures have not formed a large enough allosteric pocket to accommodate this type of binding mode. In the course of this study we discovered that the number of structurally validated type II inhibitors that can be found in the PDB and that are also represented in publicly available biochemical profiling studies of kinase inhibitors is very small. We have obtained new profiling results for several additional structurally validated type II inhibitors identified through our conformational analysis. Although the available profiling data for type II inhibitors is still much smaller than for type I inhibitors, a comparison of the two data sets supports the conclusion that type II inhibitors are more selective than type I. We comment on the possible contribution of the DFG-in to DFG-out conformational reorganization to the selectivity.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm501603h</identifier><identifier>PMID: 25478866</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Allosteric Regulation ; Allosteric Site ; Amino Acid Motifs ; Amino Acid Sequence ; Biocatalysis - drug effects ; Databases, Protein ; Humans ; Models, Molecular ; Molecular Structure ; Protein Binding ; Protein Conformation ; Protein Kinase Inhibitors - chemistry ; Protein Kinase Inhibitors - metabolism ; Protein Kinase Inhibitors - pharmacology ; Protein Kinases - chemistry ; Protein Kinases - metabolism ; Protein Structure, Tertiary ; Proteome - antagonists & inhibitors ; Proteome - chemistry ; Proteome - metabolism ; Small Molecule Libraries - chemistry ; Small Molecule Libraries - metabolism ; Small Molecule Libraries - pharmacology</subject><ispartof>Journal of medicinal chemistry, 2015-01, Vol.58 (1), p.466-479</ispartof><rights>Copyright © 2014 American Chemical Society</rights><rights>Copyright © 2014 American Chemical Society 2014 American Chemical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a471t-4e6b0107f7bf88651ea3ad573875ef57d96145419ef9b4157376c869d699672e3</citedby><cites>FETCH-LOGICAL-a471t-4e6b0107f7bf88651ea3ad573875ef57d96145419ef9b4157376c869d699672e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm501603h$$EPDF$$P50$$Gacs$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm501603h$$EHTML$$P50$$Gacs$$Hfree_for_read</linktohtml><link.rule.ids>230,315,781,785,886,2766,27081,27929,27930,56743,56793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25478866$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vijayan, R. S. K.</creatorcontrib><creatorcontrib>He, Peng</creatorcontrib><creatorcontrib>Modi, Vivek</creatorcontrib><creatorcontrib>Duong-Ly, Krisna C.</creatorcontrib><creatorcontrib>Ma, Haiching</creatorcontrib><creatorcontrib>Peterson, Jeffrey R.</creatorcontrib><creatorcontrib>Dunbrack, Roland L.</creatorcontrib><creatorcontrib>Levy, Ronald M.</creatorcontrib><title>Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>Structural coverage of the human kinome has been steadily increasing over time. The structures provide valuable insights into the molecular basis of kinase function and also provide a foundation for understanding the mechanisms of kinase inhibitors. There are a large number of kinase structures in the PDB for which the Asp and Phe of the DFG motif on the activation loop swap positions, resulting in the formation of a new allosteric pocket. We refer to these structures as “classical DFG-out” conformations in order to distinguish them from conformations that have also been referred to as DFG-out in the literature but that do not have a fully formed allosteric pocket. We have completed a structural analysis of almost 200 small molecule inhibitors bound to classical DFG-out conformations; we find that they are recognized by both type I and type II inhibitors. In contrast, we find that nonclassical DFG-out conformations strongly select against type II inhibitors because these structures have not formed a large enough allosteric pocket to accommodate this type of binding mode. In the course of this study we discovered that the number of structurally validated type II inhibitors that can be found in the PDB and that are also represented in publicly available biochemical profiling studies of kinase inhibitors is very small. We have obtained new profiling results for several additional structurally validated type II inhibitors identified through our conformational analysis. Although the available profiling data for type II inhibitors is still much smaller than for type I inhibitors, a comparison of the two data sets supports the conclusion that type II inhibitors are more selective than type I. We comment on the possible contribution of the DFG-in to DFG-out conformational reorganization to the selectivity.</description><subject>Allosteric Regulation</subject><subject>Allosteric Site</subject><subject>Amino Acid Motifs</subject><subject>Amino Acid Sequence</subject><subject>Biocatalysis - drug effects</subject><subject>Databases, Protein</subject><subject>Humans</subject><subject>Models, Molecular</subject><subject>Molecular Structure</subject><subject>Protein Binding</subject><subject>Protein Conformation</subject><subject>Protein Kinase Inhibitors - chemistry</subject><subject>Protein Kinase Inhibitors - metabolism</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Protein Kinases - chemistry</subject><subject>Protein Kinases - metabolism</subject><subject>Protein Structure, Tertiary</subject><subject>Proteome - antagonists & inhibitors</subject><subject>Proteome - chemistry</subject><subject>Proteome - metabolism</subject><subject>Small Molecule Libraries - chemistry</subject><subject>Small Molecule Libraries - metabolism</subject><subject>Small Molecule Libraries - pharmacology</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>N~.</sourceid><sourceid>EIF</sourceid><recordid>eNptkV9rFDEUxYModlt98AtIXgT7MG3-Z-ZFqKttl1YqWH0NmZmkk2Um2SYZYf30Ztm6KPhy78P9nXMPHADeYHSGEcHn64kjLBAdnoEF5gRVrEbsOVggREhFBKFH4DilNUKIYkJfgiPCmaxrIRbg1zJ4G-Kkswtej_CijG1yCQYL82Dgp8ur6m7O8MZ5nQz8ErKzUPsefnShG8zkuiL6GoN1o_MPO9W3HOcuz1GP4xb-0KPrdTY9vN9uDFyt4MoPrnU5xPQKvLB6TOb10z4B3y8_3y-vq9u7q9Xy4rbSTOJcMSNahJG0srUlM8dGU91zSWvJjeWybwRmnOHG2KZluByk6GrR9KJphCSGnoAPe9_N3E6m74zPJZzaRDfpuFVBO_XvxbtBPYSfilEiZCOLwfsngxgeZ5OymlzqzDhqb8KcFBaMS0kF2aGne7SLIaVo7OENRmrXlTp0Vdi3f-c6kH_KKcC7PaC7pNZhjqWb9B-j3xOBnAE</recordid><startdate>20150108</startdate><enddate>20150108</enddate><creator>Vijayan, R. S. K.</creator><creator>He, Peng</creator><creator>Modi, Vivek</creator><creator>Duong-Ly, Krisna C.</creator><creator>Ma, Haiching</creator><creator>Peterson, Jeffrey R.</creator><creator>Dunbrack, Roland L.</creator><creator>Levy, Ronald M.</creator><general>American Chemical Society</general><scope>N~.</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150108</creationdate><title>Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors</title><author>Vijayan, R. S. K. ; He, Peng ; Modi, Vivek ; Duong-Ly, Krisna C. ; Ma, Haiching ; Peterson, Jeffrey R. ; Dunbrack, Roland L. ; Levy, Ronald M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a471t-4e6b0107f7bf88651ea3ad573875ef57d96145419ef9b4157376c869d699672e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Allosteric Regulation</topic><topic>Allosteric Site</topic><topic>Amino Acid Motifs</topic><topic>Amino Acid Sequence</topic><topic>Biocatalysis - drug effects</topic><topic>Databases, Protein</topic><topic>Humans</topic><topic>Models, Molecular</topic><topic>Molecular Structure</topic><topic>Protein Binding</topic><topic>Protein Conformation</topic><topic>Protein Kinase Inhibitors - chemistry</topic><topic>Protein Kinase Inhibitors - metabolism</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Protein Kinases - chemistry</topic><topic>Protein Kinases - metabolism</topic><topic>Protein Structure, Tertiary</topic><topic>Proteome - antagonists & inhibitors</topic><topic>Proteome - chemistry</topic><topic>Proteome - metabolism</topic><topic>Small Molecule Libraries - chemistry</topic><topic>Small Molecule Libraries - metabolism</topic><topic>Small Molecule Libraries - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vijayan, R. S. K.</creatorcontrib><creatorcontrib>He, Peng</creatorcontrib><creatorcontrib>Modi, Vivek</creatorcontrib><creatorcontrib>Duong-Ly, Krisna C.</creatorcontrib><creatorcontrib>Ma, Haiching</creatorcontrib><creatorcontrib>Peterson, Jeffrey R.</creatorcontrib><creatorcontrib>Dunbrack, Roland L.</creatorcontrib><creatorcontrib>Levy, Ronald M.</creatorcontrib><collection>American Chemical Society (ACS) Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vijayan, R. S. K.</au><au>He, Peng</au><au>Modi, Vivek</au><au>Duong-Ly, Krisna C.</au><au>Ma, Haiching</au><au>Peterson, Jeffrey R.</au><au>Dunbrack, Roland L.</au><au>Levy, Ronald M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2015-01-08</date><risdate>2015</risdate><volume>58</volume><issue>1</issue><spage>466</spage><epage>479</epage><pages>466-479</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><abstract>Structural coverage of the human kinome has been steadily increasing over time. The structures provide valuable insights into the molecular basis of kinase function and also provide a foundation for understanding the mechanisms of kinase inhibitors. There are a large number of kinase structures in the PDB for which the Asp and Phe of the DFG motif on the activation loop swap positions, resulting in the formation of a new allosteric pocket. We refer to these structures as “classical DFG-out” conformations in order to distinguish them from conformations that have also been referred to as DFG-out in the literature but that do not have a fully formed allosteric pocket. We have completed a structural analysis of almost 200 small molecule inhibitors bound to classical DFG-out conformations; we find that they are recognized by both type I and type II inhibitors. In contrast, we find that nonclassical DFG-out conformations strongly select against type II inhibitors because these structures have not formed a large enough allosteric pocket to accommodate this type of binding mode. In the course of this study we discovered that the number of structurally validated type II inhibitors that can be found in the PDB and that are also represented in publicly available biochemical profiling studies of kinase inhibitors is very small. We have obtained new profiling results for several additional structurally validated type II inhibitors identified through our conformational analysis. Although the available profiling data for type II inhibitors is still much smaller than for type I inhibitors, a comparison of the two data sets supports the conclusion that type II inhibitors are more selective than type I. We comment on the possible contribution of the DFG-in to DFG-out conformational reorganization to the selectivity.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>25478866</pmid><doi>10.1021/jm501603h</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-2623 |
ispartof | Journal of medicinal chemistry, 2015-01, Vol.58 (1), p.466-479 |
issn | 0022-2623 1520-4804 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4326797 |
source | MEDLINE; ACS Publications |
subjects | Allosteric Regulation Allosteric Site Amino Acid Motifs Amino Acid Sequence Biocatalysis - drug effects Databases, Protein Humans Models, Molecular Molecular Structure Protein Binding Protein Conformation Protein Kinase Inhibitors - chemistry Protein Kinase Inhibitors - metabolism Protein Kinase Inhibitors - pharmacology Protein Kinases - chemistry Protein Kinases - metabolism Protein Structure, Tertiary Proteome - antagonists & inhibitors Proteome - chemistry Proteome - metabolism Small Molecule Libraries - chemistry Small Molecule Libraries - metabolism Small Molecule Libraries - pharmacology |
title | Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T21%3A01%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Conformational%20Analysis%20of%20the%20DFG-Out%20Kinase%20Motif%20and%20Biochemical%20Profiling%20of%20Structurally%20Validated%20Type%20II%20Inhibitors&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Vijayan,%20R.%20S.%20K.&rft.date=2015-01-08&rft.volume=58&rft.issue=1&rft.spage=466&rft.epage=479&rft.pages=466-479&rft.issn=0022-2623&rft.eissn=1520-4804&rft_id=info:doi/10.1021/jm501603h&rft_dat=%3Cproquest_pubme%3E1645773627%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1645773627&rft_id=info:pmid/25478866&rfr_iscdi=true |